TCGA-CV-A6K2-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.072374429
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.430
- INTERFERON_ALPHA_RESPONSE+0.340
- OXIDATIVE_PHOSPHORYLATION+0.310
- COMPLEMENT+0.300
- INFLAMMATORY_RESPONSE+0.300
- TGF_BETA_SIGNALING+0.290
- INTERFERON_GAMMA_RESPONSE+0.270
- CHOLESTEROL_HOMEOSTASIS+0.260
- TNFA_SIGNALING_VIA_NFKB+0.260
- IL6_JAK_STAT3_SIGNALING+0.250
Top 10 suppressed
- MYC_TARGETS_V2-0.440
- MYOGENESIS-0.410
- SPERMATOGENESIS-0.260
- WNT_BETA_CATENIN_SIGNALING-0.250
- KRAS_SIGNALING_DN-0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- HEDGEHOG_SIGNALING-0.130
- E2F_TARGETS-0.120
- APICAL_JUNCTION-0.100
- APICAL_SURFACE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168598 | — | — | 0.784 |
| 2 | BS_XF0ZX2B3 | Supratentorial Ependymoma | — | 0.735 |
| 3 | BS_49852ZBH | pilocytic astrocytoma | — | 0.731 |
| 4 | BS_E3EJHXQV | low-grade glioma | — | 0.728 |
| 5 | BS_NS7GSHB9 | pilocytic astrocytoma | — | 0.724 |
| 6 | SRR12696744 | — | — | 0.722 |
| 7 | TCGA-44-2656-01A-02R-0946-07 | — | cohortA1 | 0.717 |
| 8 | TCGA-CQ-7071-01A-12R-A30B-07 | — | — | 0.715 |
| 9 | TCGA-CQ-6223-01A-11R-1915-07 | — | — | 0.712 |
| 10 | 31D3488A-212B-4818-8F09-EBF1E8B135AD | — | — | 0.711 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |